Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Liminal BioSciences Inc. LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

Recent & Breaking News (NDAQ:LMNL)

Liminal BioSciences to Divest Bioseparations Division to KKR

Canada NewsWire November 4, 2019

Liminal BioSciences announces upcoming presentations new data on pulmonary arterial hypertension at the 2019 AHA meeting

Canada NewsWire October 29, 2019

Liminal BioSciences announces upcoming presentations at The Liver Meeting 2019

Canada NewsWire October 25, 2019

Liminal BioSciences Announces Upcoming Presentations at ASN Kidney Week 2019

Canada NewsWire October 24, 2019

Liminal BioSciences to Present At H.C. Wainwright & Co. 3rd Annual NASH Investor Conference

Canada NewsWire October 18, 2019

Prometic Shareholders Approve Name Change to Liminal BioSciences Inc.

Canada NewsWire October 3, 2019

Prometic Reports First Subject Dosed in Phase I Clinical Study with Single Ascending Doses of PBI-4547

Canada NewsWire September 9, 2019

Prometic Life Sciences to Present at H.C. Wainwright & Co. 21st Annual Global Investment Conference

Canada NewsWire September 4, 2019

Prometic Life Sciences Announces Intention to Change Name to Liminal BioSciences Inc.

Canada NewsWire September 3, 2019

Prometic reports financial results for second quarter 2019

Canada NewsWire August 12, 2019

Correction of previous press release: Prometic to report its second quarter financial results and hold conference call

Canada NewsWire August 8, 2019

Prometic to report its second quarter financial results and hold conference call

Canada NewsWire August 7, 2019

Prometic Life Sciences to Present at Canaccord 39th Annual Growth Conference

Canada NewsWire August 5, 2019

Prometic Announces Share Consolidation

Canada NewsWire July 2, 2019

Prometic Announces Voting Results of its 2019 AGM

Canada NewsWire June 19, 2019

Prometic announces completion of equity rights offering

Canada NewsWire June 17, 2019

Prometic Presents New Data on PBI-4050 and its Mechanism of Action on Kidney Fibrosis at the 56th ERA/EDTA Congress

Canada NewsWire June 14, 2019

Prometic Life Sciences to Present at Two Upcoming June Investor Conferences

Canada NewsWire May 30, 2019

Prometic presents new PBI-4050 and Ryplazim(TM) (plasminogen) data on lung fibrosis at the 2019 ATS Conference

Canada NewsWire May 22, 2019

Prometic announces terms of equity rights offering

Canada NewsWire May 15, 2019